Stride vs Universal Technical Institute
LRN and UTI side by side, both in services-educational services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LRN and UTI compare
Stride is the larger company, worth 2.6 times as much as Universal Technical Institute ($3.2B against $1.2B).
On earnings, Stride is cheaper: it trades at 10.5× trailing earnings, against 35.5× for Universal Technical Institute.
Universal Technical Institute grew revenue faster over the last twelve months (9.1% versus 2.5% for Stride).
Stride keeps more of each dollar of sales as profit, with a net margin of 13.2% compared with 3.9% at Universal Technical Institute.
Stride scores higher on the StockData Score (20 against 10 for Universal Technical Institute), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LRN | UTI |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $1.2B |
| Share price | $75.82 | $21.99 |
| Change, 1 year | 15.6% | −26.6% |
| Change, 5 years | 104% | 159% |
| Beta (5Y) | 0.37 | 0.75 |
| Employees | 9,200 | 4,100 |
| StockData Score | ||
| Total score | 20 (better) | 10 |
| Valuation score | 6 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 6 (better) | 4 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.5× (better) | 35.5× |
| P/S | 1.3× (better) | 1.4× |
| P/B | 1.9× (better) | 3.5× |
| EV/EBITDA | 4.7× (better) | 14.8× |
| P/FCF | 6.3× | – |
| PEG | 0.31 (better) | 0.81 |
| FCF yield | 15.8% (better) | −1.9% |
| Fair value | $116.44 | $14.05 |
| Margin of safety | 34.9% (better) | −56.5% |
| Growth | ||
| Revenue growth (TTM) | 2.5% | 9.1% (better) |
| Revenue growth, 5Y average | 10.4% | 22.7% (better) |
| Net income growth (TTM) | 5.8% (better) | −45.7% |
| EPS growth (TTM) | 12.1% (better) | −45.1% |
| EPS growth, 5Y average | 33.1% | 86.6% (better) |
| Profitability | ||
| Gross margin | 37.4% | – |
| Operating margin | 18.4% (better) | 5.0% |
| Net margin | 13.2% (better) | 3.9% |
| FCF margin | 19.9% (better) | −2.6% |
| Return on equity | 20.9% (better) | 10.5% |
| Return on invested capital | 28.0% (better) | 10.4% |
| Financial health | ||
| Debt / equity | 0.25 (better) | 0.46 |
| Net debt / EBITDA | −0.62 | −0.12 |
| Interest coverage | – | 11.4× |
| Current ratio | 2.56 (better) | 1.30 |
| Altman Z-score | 5.03 (better) | 2.72 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 112% | 113% |
| Held by insiders | 8.8% | 35.5% |
| Insider net buying, 12 months | $39.6M (better) | −$104M |
| Short interest, % of float | 18.0% | 21.7% |
Go deeper
- LRN stock overview
- LRN income statement
- LRN valuation and score
- UTI stock overview
- UTI income statement
- UTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.